Xiao Hui Gu
Geen lopende functies
Loopbaan van Xiao Hui Gu
Eerdere bekende functies van Xiao Hui Gu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01-01-2008 | 01-01-2008 |
| EXELIXIS, INC. | Corporate Officer/Principal | - | - |
| PHARMARON BEIJING CO., LTD. | Corporate Officer/Principal | 01-05-2011 | - |
Opleiding van Xiao Hui Gu
| Hunan Normal University | Undergraduate Degree |
| Shanghai Institute of Organic Chemistry | Doctorate Degree |
Statistieken
Internationaal
| China | 4 |
| Verenigde Staten | 3 |
Operationeel
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Commercial Services | 3 |
| Consumer Services | 3 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PHARMARON BEIJING CO., LTD. | Commercial Services |
| EXELIXIS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Beurs
- Insiders
- Xiao Hui Gu
- Ervaring
